Syndax Pharmaceuticals, Inc.
SNDX
Positions held
Your positionsSNDX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Syndax Pharmaceuticals is positioned in the growing biotechnology sector, focusing on innovative cancer therapies that address unmet medical needs.
- Revenue increased by 12% compared to the prior quarter, reaching $73 million.
- Gross margin remains high at 95.6%, indicating strong product profitability.
- The company has a negative profit margin of -87.52%, reflecting ongoing financial challenges.
- Syndax's debt-to-equity ratio is extremely high at 3903.45, raising concerns about financial stability.
- The stock has a recommendation of 'Sell' with a score of -12.00, indicating bearish sentiment among analysts.
Fundamentals
| Market cap | $1.51B | Enterprise value | $1.54B | Trailing P/E | — | Forward P/E | -19.79 |
| PEG | — | Price / book | 100.00 | Beta | 0.42 | Dividend yield | 0.00% |
| Revenue growth | 91.8% | Earnings growth | — | Gross margin | -8.0% | Operating margin | -54.9% |
| Profit margin | -87.5% | ROE | -2.6% | ROA | -18.7% | Debt / equity | 39.03 |
| Current ratio | 6.77 | Free cash flow | -$150.08M | Analyst recommendation | strong_buy | Mean target | $37.55 |
| 52w high | $25.59 | 52w low | $12.99 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $72.8M | $64.9M | $68.7M | $45.9M | $38.0M | — |
| Op margin | -54.9% | -52.7% | -91.0% | -125.2% | -182.7% | — |
| Net income | -$49.4M | -$42.7M | -$68.0M | -$60.7M | -$71.8M | — |
| Gross margin | 95.6% | 95.9% | 96.1% | 95.4% | 96.6% | — |
| Gross profit | $69.6M | $62.2M | $66.0M | $43.8M | $36.7M | — |
| Operating income | -$40.0M | -$34.2M | -$62.5M | -$57.4M | -$69.4M | — |
- Revenue +12% vs prior quarter ($73M vs $65M).
- Gross margin 95.6% (was 96% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $172M | $23.7M | $0.0M | $0.0M | — |
| Op margin | -158.4% | -1434.4% | — | — | — |
| Net income | -$285M | -$319M | -$209M | -$149M | — |
| Gross margin | 96.0% | 96.5% | — | — | — |
| Gross profit | $165M | $22.9M | $0.0M | $0.0M | — |
| Operating income | -$273M | -$340M | -$230M | -$152M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-09-29 · Claude AI Just Bought These 2 Pharma Stocks
2026-09-04 · Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-09-01 · Syndax Announces Participation in September Investor Conferences
2026-08-22 · Citi Predicts Up to 410% Rally for These 2 ‘Strong Buy’ Stocks
2026-08-21 · UBS Adjusts Price Target on Syndax Pharmaceuticals to $33 From $37, Keeps Buy Rating
2026-08-12 · Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall?
2026-08-12 · Syndax (SNDX) Q2 2026 Earnings Call Transcript
2026-08-07 · How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors
2026-08-05 · Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-08-05 · Syndax Pharmaceuticals Inc (SNDX) (Q2 2026) Earnings Call Highlights: Revenue Surges 92% as ...
2026-08-05 · Syndax Pharmaceuticals Q2 Earnings Call Highlights
Price (daily)
Full chart · RSI · MACD · patterns